Key result
Early Highly Effective Disease Modifying Treatment (HET) or escalation to HET resulted in No Evidence of Disease Activity-3 (NEDA-3) in 80% of pediatric-onset multiple sclerosis patients at 3 years.
Why the study?
Pediatric-Onset Multiple Sclerosis is characterized by high inflammatory disease activity, prompting a need to describe treatment sequencing and the impact of highly effective disease modifying treatment on disease activity.
Does Highly Effective Disease Modifying Treatment (HET) improve disease activity in patients with Pediatric-Onset Multiple Sclerosis?
Observational (n=5)
Does Highly Effective Disease Modifying Treatment (HET) improve disease activity in patients with Pediatric-Onset Multiple Sclerosis?
Early initiation or escalation to highly effective disease-modifying treatment in pediatric-onset multiple sclerosis resulted in 80% of patients achieving no evidence of disease activity.
Introduction: Pediatric-Onset Multiple Sclerosis (POMS) is characterized by high inflammatory disease activ-ity. Our aim was to describe the treatment sequencing and report the impact Highly Effective Disease Modifying Treatment (HET) had on disease activity. Materials and Methods: 2/5 consecutive POMS were administered HET as initial therapy after diagnosis. Data on treatment sequencing, relapses and MRIs were collected during the follow-up. Results: Our patients had an average age of 13.8 years (range 9-17) at di-agnosis and 13.4 years (range 9-16) at disease onset, 2/5 (40%) POMS were female. The pre-treatment aver-age annualized relapse rate was 1.6 (range 0.8-2.8) and the average follow-up length was 5 years (range 3-7). A total of 2/5 (40%) patients were stable on HET at initial therapy, 3/5 (60%) required an escalation to more aggressive treatment, even if two of them had been put on HET as initial treatment. Four out of five patients (80%) had No Evidence of Disease Activity-3 status (NEDA-3) at an average follow-up of 3 years (range 2-5). Conclusion: it has been observed that in a recent time period all the cases had prompt diagnosis, early HET or escalation to HET with a good outcome in 80% of the cases.
No takes yet. Share an insight, caveat, or question.
Immovilli et al. (2022) conducted an observational in Pediatric-Onset Multiple Sclerosis (n=5). Highly Effective Disease Modifying Treatment (HET) was evaluated on No Evidence of Disease Activity-3 status (NEDA-3). Early Highly Effective Disease Modifying Treatment (HET) or escalation to HET resulted in No Evidence of Disease Activity-3 (NEDA-3) in 80% of pediatric-onset multiple sclerosis patients at 3 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: